nctId: NCT06345508 id: 2024-12161 briefTitle: Early Detection of Liver Cancer by QUS acronym: QUS in HCC overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-06 date: 2029-12 date: 2024-04-03 date: 2024-04-12 name: Centre hospitalier de l'Université de Montréal (CHUM) class: OTHER name: Centre de Recherche du Centre Hospitalier de l'Université de Montréal name: Canadian Institutes of Health Research (CIHR) briefSummary: Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location, size, and extent of disease. Medical societies therefore recommend surveillance with ultrasound every 6 months in at-risk patients. However, a key challenge to improving the survival is that ultrasound may miss half of early-stage liver cancers, thus diagnosis must rely on additional tests such as computed tomography (CT), magnetic resonance imaging (MRI), or biopsy. Hence, there is a clear need to improve the ability to detect liver cancers, especially with ultrasound. The investigator's team proposes novel ultrasound approaches to detect cancer nodules invisible on conventional ultrasound based on differences in mechanical and structural properties between liver and tumor. Improving detection is critical because liver cancer can be cured only if detected at an early stage, as shown by improvements in survival rates in patients enrolled in surveillance programs. The investigator's multi-disciplinary, national, and international team includes experts in clinical fields (hepatology, oncology, radiology, pathology), basic sciences (engineering, medical physics, machine learning, biostatistics), and patient partnership. The investirgator will apply the methodology of patient partner recruitment and collaborate with the Centre of Excellence on Partnership with Patients and the Public to select potential new collaborators. This will permit this project to be informed at every stage by patient and family perspectives, ensuring that the results of this project will be more robust, impactful, and aligned with the priorities, needs and experiences of those who live with liver cancer. The investigator submits a research proposal focused on advanced imaging techniques because imaging constitutes a foundation for surveillance, diagnosis, staging, treatment selection and assessment of treatment response in patients with liver cancer. conditions: Hepatocellular Carcinoma conditions: Liver Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 328 type: ESTIMATED name: Quantitative Ultrasound name: B-mode Ultrasound name: Magnetic Resonance Imaging name: Liver Biopsy measure: Compare the sensitivity of QUS + B-mode US vs B-mode US alone for lesion detection, using MRI as the reference standard for detection measure: Compare the specificity of QUS + B-mode US vs B-mode US alone for diagnosis of HCC, using MRI or biopsy as the composite reference standard for classification measure: Determine the lesion-to-liver contrast of investigational QUS techniques for detection of HCC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier de l'Université de Montréal (CHUM) city: Montréal state: Quebec zip: H2X 0A9 country: Canada name: An Tang, MD, MSc role: CONTACT phone: 514-890-8000 phoneExt: 36400 email: an.tang@umontreal.ca name: Casey Bourdeau Caporuscio, MSc role: CONTACT phone: 514-890-8000 phoneExt: 14756 email: casey.bourdeau-caporuscio.chum@ssss.gouv.qc.ca name: An Tang, MD, MSc role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False